SG11202005009RA - MODIFIED Cκ AND CH1 DOMAINS - Google Patents

MODIFIED Cκ AND CH1 DOMAINS

Info

Publication number
SG11202005009RA
SG11202005009RA SG11202005009RA SG11202005009RA SG11202005009RA SG 11202005009R A SG11202005009R A SG 11202005009RA SG 11202005009R A SG11202005009R A SG 11202005009RA SG 11202005009R A SG11202005009R A SG 11202005009RA SG 11202005009R A SG11202005009R A SG 11202005009RA
Authority
SG
Singapore
Prior art keywords
domains
modified
Prior art date
Application number
SG11202005009RA
Inventor
Yongqiang Wang
Lei Fang
Zhengyi Wang
Bingshi Guo
Jingwu Zang
Original Assignee
I Mab Biopharma Us Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Us Ltd filed Critical I Mab Biopharma Us Ltd
Publication of SG11202005009RA publication Critical patent/SG11202005009RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11202005009RA 2018-01-15 2019-01-15 MODIFIED Cκ AND CH1 DOMAINS SG11202005009RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018072564 2018-01-15
PCT/CN2019/071740 WO2019137552A1 (en) 2018-01-15 2019-01-15 MODIFIED Cκ AND CH1 DOMAINS

Publications (1)

Publication Number Publication Date
SG11202005009RA true SG11202005009RA (en) 2020-06-29

Family

ID=67219407

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005009RA SG11202005009RA (en) 2018-01-15 2019-01-15 MODIFIED Cκ AND CH1 DOMAINS

Country Status (14)

Country Link
US (1) US20190389972A1 (en)
EP (1) EP3577141A4 (en)
JP (1) JP6996825B2 (en)
KR (1) KR102471868B1 (en)
CN (1) CN110573531B (en)
AU (2) AU2019203917B2 (en)
BR (1) BR112020009414A2 (en)
CA (1) CA3084398A1 (en)
EA (1) EA202091053A1 (en)
IL (1) IL275943B (en)
MX (1) MX2020006942A (en)
SG (1) SG11202005009RA (en)
WO (1) WO2019137552A1 (en)
ZA (1) ZA202002567B (en)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009541275A (en) * 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス Production of bispecific antibodies
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
US9738707B2 (en) * 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
EP2915819B1 (en) * 2012-11-05 2019-08-14 Zenyaku Kogyo Kabushikikaisha Antibody and antibody composition production method
EP2970435B1 (en) * 2013-03-15 2020-08-12 Eli Lilly and Company Methods for producing fabs and bi-specific antibodies
UA117289C2 (en) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Multispecific antibodies
US10392438B2 (en) * 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
EP4026850A1 (en) * 2014-05-28 2022-07-13 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
MY191428A (en) * 2014-11-14 2022-06-27 Hoffmann La Roche Antigen binding molecules comprising a tnf family ligand trimer
EP3356420B1 (en) * 2015-10-02 2023-11-01 F. Hoffmann-La Roche AG Multispecific antibodies
EP3150636A1 (en) * 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
AU2016368469B2 (en) * 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
WO2017117179A1 (en) * 2015-12-28 2017-07-06 Massachusetts Institute Of Technology Bispecific antibodies having constant region mutations and uses therefor
EP3433273B1 (en) * 2016-03-25 2021-12-29 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1

Also Published As

Publication number Publication date
EP3577141A1 (en) 2019-12-11
US20190389972A1 (en) 2019-12-26
AU2019203917A1 (en) 2019-08-01
KR20200059186A (en) 2020-05-28
AU2019203917B2 (en) 2020-04-02
JP6996825B2 (en) 2022-01-17
EA202091053A1 (en) 2020-12-03
KR102471868B1 (en) 2022-11-30
MX2020006942A (en) 2020-09-14
JP2021506747A (en) 2021-02-22
BR112020009414A2 (en) 2020-11-03
CN110573531A (en) 2019-12-13
ZA202002567B (en) 2021-04-28
CN110573531B (en) 2021-04-02
AU2020203065A1 (en) 2020-05-28
WO2019137552A1 (en) 2019-07-18
EP3577141A4 (en) 2021-02-17
AU2020203065B2 (en) 2023-04-06
IL275943B (en) 2022-06-01
CA3084398A1 (en) 2019-07-18
IL275943A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
IL276950A (en) Anti-cd73 antibodies and uses thereof
IL282968A (en) Anti-nkg2a antibodies and uses thereof
ZA202103260B (en) Pyridazinone compounds and uses thereof
ZA202103231B (en) Pyridazinone compounds and uses thereof
GB201803568D0 (en) Novel compounds and uses
SG11202101675UA (en) Anti-bcma single domain antibodies and application thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
IL281297A (en) Anti-npr1 antibodies and uses thereof
IL282707A (en) Anti-tim-3 antibodies and their use
IL282708A (en) Anti-tim-3 antibodies and their use
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL277330A (en) Anti-il-27 antibodies and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL281202A (en) Anti-tnfrsf9 antibodies and uses thereof
IL277075A (en) Anti-phf-tau antibodies and uses thereof
IL276548A (en) Bcma-binding antibodies and uses thereof
IL280644A (en) Magnesium-serinate compound and use thereof
IL279483A (en) Cyanotriazole compounds and uses thereof
IL277502A (en) Compounds and uses thereof
IL283890A (en) Anti-periostin antibodies and uses thereof
IL277749A (en) Pladienolide compounds and their use
KR102292781B9 (en) - PolyglycolidePGA-polylactidePLA muliblock copolymer and method of synthesis of the same
GB201801102D0 (en) New compounds and uses
IL280369A (en) New myokines and uses thereof